JJ

Janvi Jayesh Patil

Active Director Director DIN 10633652
DIN 10633652 First appointment May 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Janvi Jayesh Patil

Data last updated:

Janvi Jayesh Patil is a Director at Metagen Pharmaceutical Private Limited (since 2024). The company operates in Pharma.

DIN 10633652
Primary Designation Director
Industry Pharma
First Appointment 20 May 2024
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 May 20242022Active

Directorship timeline

Open interactive timeline →
Metagen Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Janvi Jayesh Patil

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Janvi Jayesh Patil

Janvi Jayesh Patil currently holds 1 directorship: Metagen Pharmaceutical Private Limited (Director, since 20 May 2024).

Janvi Jayesh Patil was first appointed on 20 May 2024 as Director at Metagen Pharmaceutical Private Limited.

The current boards of Janvi Jayesh Patil's companies include Amey Vikas Patil (Metagen Pharmaceutical Private Limited), Atul Chandrakant Pimple (Metagen Pharmaceutical Private Limited), Kiran Arun More (Metagen Pharmaceutical Private Limited), Peter Philip Fernandes (Metagen Pharmaceutical Private Limited), Sagar Devram Shinde (Metagen Pharmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available